| Mechanosensitive caveolin-1 activation-induced PI3K/Akt/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis in vivo H Yang, L Guan, S Li, Y Jiang, N Xiong, L Li, C Wu, H Zeng, Y Liu Oncotarget 7 (13), 16227, 2016 | 141 | 2016 |
| Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma JF Liu, N Xiong, SM Campos, AA Wright, C Krasner, S Schumer, ... Journal of Clinical Oncology 39 (14), 1531-1539, 2021 | 121 | 2021 |
| MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial–mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells S Li, J Lu, Y Chen, N Xiong, L Li, J Zhang, H Yang, C Wu, H Zeng, Y Liu Cellular & molecular immunology 14 (7), 621-630, 2017 | 101 | 2017 |
| Involvement of caveolin-1 in low shear stress-induced breast cancer cell motility and adhesion: roles of FAK/Src and ROCK/p-MLC pathways N Xiong, S Li, K Tang, H Bai, Y Peng, H Yang, C Wu, Y Liu Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1864 (1), 12-22, 2017 | 68 | 2017 |
| Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial EK Lee, N Xiong, SC Cheng, WT Barry, RT Penson, ... Gynecologic Oncology 159 (1), 72-78, 2020 | 61 | 2020 |
| Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway L Li, J Zhang, N Xiong, S Li, Y Chen, H Yang, C Wu, H Zeng, Y Liu Medical Oncology 33, 1-11, 2016 | 55 | 2016 |
| A phase II, two-stage study of Letrozole and Abemaciclib in estrogen receptor–positive recurrent endometrial cancer PA Konstantinopoulos, EK Lee, N Xiong, C Krasner, S Campos, DL Kolin, ... Journal of Clinical Oncology 41 (3), 599-608, 2023 | 43 | 2023 |
| Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer F Batalini, N Xiong, N Tayob, M Polak, J Eismann, LC Cantley, GI Shapiro, ... Clinical Cancer Research 28 (8), 1493-1499, 2022 | 43 | 2022 |
| Acidic pHe regulates cytoskeletal dynamics through conformational integrin β1 activation and promotes membrane protrusion S Li, N Xiong, Y Peng, K Tang, H Bai, X Lv, Y Jiang, X Qin, H Yang, C Wu, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1864 (7 …, 2018 | 40 | 2018 |
| Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers F Batalini, DC Gulhan, V Mao, A Tran, M Polak, N Xiong, N Tayob, ... Clinical Cancer Research 28 (21), 4714-4723, 2022 | 29 | 2022 |
| Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer PA Konstantinopoulos, AA Gockley, N Xiong, C Krasner, N Horowitz, ... JAMA oncology 8 (9), 1317-1322, 2022 | 28 | 2022 |
| Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer RA Pozzar, N Xiong, F Hong, AA Wright, BA Goff, ML Underhill-Blazey, ... Gynecologic oncology 163 (2), 408-418, 2021 | 26 | 2021 |
| Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: results from a multi-site randomized trial DL Berry, F Hong, TM Blonquist, B Halpenny, N Xiong, CP Filson, ... Urologic Oncology: Seminars and Original Investigations 39 (8), 493. e9-493. e15, 2021 | 16 | 2021 |
| Clinical decision support for symptom management in lung cancer patients: a group RCT ME Cooley, E Mazzola, N Xiong, F Hong, DF Lobach, IM Braun, ... Journal of pain and symptom management 63 (4), 572-580, 2022 | 15 | 2022 |
| Mixed‐methods analysis of decisional regret in parents following a child's death from cancer D Feifer, EG Broden, N Xiong, E Mazzola, JN Baker, J Wolfe, JM Snaman Pediatric Blood & Cancer 70 (10), e30541, 2023 | 11 | 2023 |
| A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma EH Stover, N Xiong, AP Myers, N Tayob, V Engvold, M Polak, ... Gynecologic Oncology Reports 40, 100974, 2022 | 11 | 2022 |
| LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer PA Konstantinopoulos, AA Gockley, N Xiong, N Tayob, CN Krasner, ... Annals of Oncology 31, S1165, 2020 | 11 | 2020 |
| A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. JF Liu, N Xiong, SM Campos, AA Wright, CN Krasner, ST Schumer, ... Journal of Clinical Oncology 38 (15_suppl), 6009-6009, 2020 | 10 | 2020 |
| Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer RA Pozzar, F Hong, N Xiong, JE Stopfer, MM Nayak, M Underhill-Blazey Familial Cancer, 1-13, 2021 | 8 | 2021 |
| Stepping into survivorship pilot study: harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors E Schrier, N Xiong, E Thompson, H Poort, S Schumer, JF Liu, C Krasner, ... Gynecologic oncology 161 (2), 581-586, 2021 | 7 | 2021 |
